Previous Page  23 / 50 Next Page
Information
Show Menu
Previous Page 23 / 50 Next Page
Page Background

Neumol Pediatr 2015; 10 (3): 111 - 117

C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl

117

La nueva displasia broncopulmonar desde el punto de vista del neumólogo pediatra

19. Rhein L, Simoneau T, Davis J, Correia C, Ferrari D, Monuteaux

M, Gregory M. Reference values of nocturnal oxygenation for

use in outpatient oxygen weaning protocols in premature infants.

Pediatr Pulmonol 2012;47:453-9

20. Brockmann PE, Poets A, Urschitz MS, Sokollik C, Poets CF.

Reference values for pulse oximetry recordings in healthy term

neonates during their first 5 days of life. Arch Dis Child Fetal

Neonatal 2011;96:F335-8

21. Mandy G, Malkar M, Welty S, Brown R, Shepherd E, Gardner

W, Moise A, Gest A. Tracheostomy Placement in Infants With

Bronchopulmonary Dysplasia: Safety and Outcomes Pediatr

Pulmonol 2013;48:245–249

22. Darlow BA, Graham PJ. Vitamin A supplementation to

prevent mortality and short and long-term morbidity in very

low birthweight infants. Cochrane Database Syst Rev 2007 Oct

17;CD000501

23. Nair V, Loganathan P, Soraisham AS. Azithromycin and other

macrolides for prevention of bronchopulmonary dysplasia: a

systematic review and meta-analysis. Neonatol 2014;106:337-47

24. Grier D, Halliday L. Effects of Glucocorticoids on Fetal and

Neonatal Lung Development Treatments. Respir Med 2004, 3:

295-306

25. American Academy of Pediatrics, Canadian Paediatric Society

(fetus and newborn committee). Postnatal corticosteroids to treat

or prevent chronic lung disease in preterm infants. Pediatr 2002;

109: 330-38

26. Onland W, Offringa M, van Kaam A. Late (

7 days) inhalation

corticosteroids to reduce bronchopulmonary dysplasia in preterm

infants. Cochrane Database Syst Rev 2012 Apr 18;4:CD002311

27. Segar JL. Neonatal diuretic therapy: furosemide, thiazides,

and spironolactone. Clin Perinatol. 2012; 39:209-20

28. Greenough A. Long term respiratory outcomes of very

premature birth (<32 weeks). Semin Fetal Neonatal Med

2012;17:73-6

29. Updated Guidance for Palivizumab Prophylaxis Among Infants

and Young Children at Increased Risk of Hospitalization for

Respiratory Syncytial Virus Infection. Pediatr 2014, 134: 415-42

30. Hudak B, Allen M, Hudak M, Loughlin G. Home Oxygen

Therapy for Chronic Lung Disease in Extremely Low-Birth-Weight

Infants. Am J Dis Child 1989; 143: 357- 360

31. Hennessy E, Bracewell M, Wood N, Wolke D, Costeloe K,

Gibson A, Marlow N for the EPICure Study Group. Respiratory

health in pre-school and school age children following extremely

preterm birth. Arch Dis Child 2008;93:1037–1043

32. Palm K, Simoneau T, Sawicki G, Rhein L. Assessment

of Current Strategies for Weaning Premature Infants From

Supplemental Oxygen in the Outpatient Setting. Adv Neonatal

Care 2011; 11:349-356

33. Cristea A, Carroll A, Davis S, Swigonski N, Ackerman V.

Outcomes of Children With Severe Bronchopulmonary Dysplasia

Who Were Ventilator Dependent at Home. Pediatr 2013; 132:

727-734

34. Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell

V, Thomas S, and J. Stocks J. Lung Function and Respiratory

Symptoms at 11 Years in Children Born Extremely Preterm The

EPICure Study. Am J Respir Crit Care Med 2010;182: 237–245

35. Carraro S, Filippone M, Da Dalt L, Ferraro V, Maretti M, Bressan

S, El Mazloum D, Baraldi E. Bronchopulmonary dysplasia: the

earliest and perhaps the longest lasting obstructive lung disease

in humans. Early Hum De 2013; 89 Suppl 3:S3-5